Merck Millipore Enters Into Agreement to Acquire Exclusive Rights to Singulex’s Ultra-Sensitive Single Molecule Counting (SMC™) Technology

• Acquiring exclusive worldwide rights to Singulex’s SMCTM technology – instruments, assays and services – for research applications
• Expands Merck Millipore’s Protein Detection business platform with addition of the ultra-sensitive “gold standard” Erenna® immunoassay platform
• Singulex to leverage its superior immunoassay technology to create additional opportunities in existing diagnostics businesses

May 21, 2015, Darmstadt, Germany — Merck Millipore, the Life Science division of Merck, and Singulex, the developer and leading provider of Single Molecule Counting (SMCTM) technology for clinical diagnostics and scientific discovery, today announced that they have entered into a definitive agreement under which Merck Millipore will control and manage the Singulex Life Science Research business. Under the terms of the agreement, Merck Millipore will pay Singulex an upfront payment, royalties and additional payments based upon achievement of certain commercial milestones. Merck Millipore will have exclusive rights to further develop and commercialize the SMC technology for research applications worldwide.

Reliable, ultra-sensitive protein detection is a critical unmet need in life science research. Current technologies allow detection of only approximately five percent of proteins in the entire proteome due to the very low abundance of many biomarkers, leaving the vast majority of proteins virtually undetectable. The SMC technology is a novel, patented technology combining signal enhancement and background reduction coupled with low volume sampling to achieve ultra-high sensitivity protein detection. The clinical benefits of this technology have been well-established and Singulex will continue to operate a large and successful clinical service business based on novel, enabling SMC assays. Financial and other terms of the deal were not disclosed.

“This agreement is further evidence of Merck Millipore's commitment to bringing innovative technologies to our global life science customers,” said Udit Batra, President and CEO of Merck Millipore. “The Erenna® platform offers the unique advantage of unrivaled sensitivity and precision and will be a strong addition to our Protein Detection franchise.”

“We are very pleased with this strategic agreement with Merck Millipore, a world leader in life science, since it puts our unique technology into the best possible hands to optimize its commercial scale-up and market potential,” said Guido Baechler, President and CEO of Singulex. “We have established our position as a leader in high-sensitive immunoassays, and this deal enables us to leverage our superior immunoassay technology to create additional opportunities in our other diagnostic businesses, especially within the area of companion diagnostics.

About Merck Millipore
Merck Millipore is the Life Science subsidiary of Merck, Darmstadt, Germany. As part of the global Life Science business of Merck, Merck Millipore offers a broad range of innovative performance products, services and business relationships that enable our customers' success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the life science tools industry, the Life Science business of Merck serves as a strategic partner to customers and helps advance the promise of life science. Headquartered in Billerica, Massachusetts, the global business has around 10,000 employees, operations in 66 countries and 2014 revenues of €2.7 billion. Merck Millipore operates as EMD Millipore in the U.S. and Canada.

About Merck
Merck is a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials. The company has six businesses – Merck Serono, Consumer Health, Allergopharma, Biosimilars, Merck Millipore and Performance Materials – and generated sales of € 11.3 billion in 2014. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to foster the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company operates as EMD Serono, EMD Millipore and EMD Performance Materials.

For more information, please visit www.merckgroup.com

About Singulex, Inc.
Singulex is the developer and leading provider of Single Molecule Counting technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC™ technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics.

The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex currently is developing the Sgx Clarity™ System, a fully-automated in vitro diagnostics system that will bring the benefits of SMC technology to hospital and reference labs worldwide.

For more information, please visit www.singulex.com

Cautionary Note Regarding Forward-Looking Statements
This communication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other words of similar meaning in connection with future events or future operating or financial performance are often used to identify forward-looking statements. All statements in this communication, other than those relating to historical information or current conditions, are forward-looking statements. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond control of Merck KGaA, Darmstadt, Germany, which could cause actual results to differ materially from such statements.